|
Avaliação DCF da Epigral Limited (epigral.ns)
IN | Basic Materials | Chemicals | NSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Epigral Limited (EPIGRAL.NS) Bundle
Descubra o verdadeiro potencial da Epigral Limited (epigralns) com nossa calculadora DCF avançada! Ajuste as principais suposições, explore vários cenários e avalie como as mudanças afetam a avaliação da Epigral Limited (epigralns) - tudo dentro de um modelo conveniente do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,101.7 | 8,259.4 | 15,497.3 | 21,884.0 | 18,971.8 | 26,128.8 | 35,985.8 | 49,561.3 | 68,258.1 | 94,008.2 |
| Revenue Growth, % | 0 | 35.36 | 87.63 | 41.21 | -13.31 | 37.72 | 37.72 | 37.72 | 37.72 | 37.72 |
| EBITDA | 1,967.8 | 2,655.1 | 5,171.7 | 6,980.9 | 4,766.5 | 8,089.0 | 11,140.5 | 15,343.3 | 21,131.4 | 29,103.2 |
| EBITDA, % | 32.25 | 32.15 | 33.37 | 31.9 | 25.12 | 30.96 | 30.96 | 30.96 | 30.96 | 30.96 |
| Depreciation | 443.0 | 735.4 | 859.1 | 1,089.5 | 1,235.6 | 1,734.9 | 2,389.5 | 3,290.9 | 4,532.3 | 6,242.1 |
| Depreciation, % | 7.26 | 8.9 | 5.54 | 4.98 | 6.51 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 |
| EBIT | 1,524.7 | 1,919.6 | 4,312.7 | 5,891.4 | 3,530.8 | 6,354.0 | 8,751.1 | 12,052.4 | 16,599.1 | 22,861.1 |
| EBIT, % | 24.99 | 23.24 | 27.83 | 26.92 | 18.61 | 24.32 | 24.32 | 24.32 | 24.32 | 24.32 |
| Total Cash | 1.0 | 6.8 | 250.9 | 333.5 | 31.8 | 178.1 | 245.3 | 337.9 | 465.4 | 640.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 768.6 | 1,196.2 | 2,579.3 | 1,788.2 | 1,787.5 | 3,204.2 | 4,413.0 | 6,077.8 | 8,370.6 | 11,528.4 |
| Account Receivables, % | 12.6 | 14.48 | 16.64 | 8.17 | 9.42 | 12.26 | 12.26 | 12.26 | 12.26 | 12.26 |
| Inventories | 484.0 | 539.6 | 1,541.4 | 2,118.3 | 2,629.9 | 2,506.0 | 3,451.3 | 4,753.3 | 6,546.5 | 9,016.1 |
| Inventories, % | 7.93 | 6.53 | 9.95 | 9.68 | 13.86 | 9.59 | 9.59 | 9.59 | 9.59 | 9.59 |
| Accounts Payable | 467.9 | 730.5 | 881.1 | 1,101.7 | 1,652.8 | 1,878.4 | 2,587.0 | 3,562.9 | 4,907.0 | 6,758.2 |
| Accounts Payable, % | 7.67 | 8.84 | 5.69 | 5.03 | 8.71 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 |
| Capital Expenditure | -3,692.6 | -1,968.0 | -4,563.0 | -4,164.5 | -3,984.3 | -8,038.2 | -11,070.6 | -15,247.0 | -20,998.9 | -28,920.6 |
| Capital Expenditure, % | -60.52 | -23.83 | -29.44 | -19.03 | -21 | -30.76 | -30.76 | -30.76 | -30.76 | -30.76 |
| Tax Rate, % | 32.63 | 32.63 | 32.63 | 32.63 | 32.63 | 32.63 | 32.63 | 32.63 | 32.63 | 32.63 |
| EBITAT | 1,211.2 | 1,203.4 | 2,843.3 | 3,983.8 | 2,378.6 | 4,359.4 | 6,003.9 | 8,268.9 | 11,388.3 | 15,684.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,823.1 | -249.7 | -3,095.1 | 1,343.7 | -330.0 | -3,011.1 | -4,122.8 | -5,678.1 | -7,820.1 | -10,770.3 |
| WACC, % | 5.29 | 5.17 | 5.19 | 5.21 | 5.2 | 5.21 | 5.21 | 5.21 | 5.21 | 5.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -26,196.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -10,986 | |||||||||
| Terminal Value | -341,861 | |||||||||
| Present Terminal Value | -265,150 | |||||||||
| Enterprise Value | -291,347 | |||||||||
| Net Debt | 9,609 | |||||||||
| Equity Value | -300,955 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | -7,243.18 |
Benefits You Will Receive
- Comprehensive EPIGRAL Financials: Access historical and projected data for precise valuation.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Instant calculations of intrinsic value and NPV at your fingertips.
- Scenario Simulation: Analyze various scenarios to assess the future performance of Epigral Limited.
- User-Friendly and Professional Design: Tailored for industry experts while remaining easy to navigate for newcomers.
Key Features
- Real-Time EPIGRALNS Data: Comes pre-loaded with Epigral Limited’s historical financial metrics and future projections.
- Comprehensive Customization Options: Modify revenue growth rates, profit margins, cost of capital, tax liabilities, and capital expenditures.
- Interactive Valuation Framework: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Analysis: Develop various forecast scenarios to evaluate distinct valuation possibilities.
- Intuitive User Interface: Designed for ease of use, catering to both experienced professionals and newcomers.
How It Functions
- Step 1: Download the preconstructed Excel template that includes data for Epigral Limited (EPIGRALNS).
- Step 2: Navigate through the populated sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view the updated results, including Epigral Limited's (EPIGRALNS) intrinsic value.
- Step 5: Make well-informed investment choices or create reports based on the outputs.
Why Opt for the Epigral Limited Calculator?
- User-Friendly Interface: Crafted for both novices and seasoned professionals.
- Customizable Parameters: Effortlessly adjust inputs to suit your specific analysis.
- Real-Time Feedback: Observe immediate updates to Epigral’s valuation as you change the inputs.
- Pre-Configured Data: Comes equipped with Epigral Limited’s actual financial information for swift evaluations.
- Endorsed by Industry Experts: Trusted by investors and analysts for making well-informed choices.
Who Can Benefit from Epigral Limited (EPIGRALNS)?
- Investors: Enhance your decision-making process with our advanced valuation platform.
- Financial Analysts: Streamline your workflow with an easily customizable DCF model at your fingertips.
- Consultants: Effortlessly modify templates for impactful client presentations or detailed reports.
- Finance Enthusiasts: Expand your knowledge of valuation methods through practical, real-world applications.
- Educators and Students: Utilize this tool as a hands-on resource for finance education.
Overview of What the Template Includes
- Comprehensive DCF Model: Editable framework featuring detailed valuation calculations tailored for Epigral Limited (EPIGRALNS).
- Real-World Data: Historical and projected financial data for Epigral Limited (EPIGRALNS) preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis focusing on profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Clear charts and tables providing actionable results and visual representation.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.